The content on this site is intended for healthcare professionals only
Dr Tolaney speaks with ecancertv at the 2016 San Antonio Breast Cancer Symposium about results from a phase Ib/II study of anti-PD-1 pembrolizumab with eribulin mesylate, a microtubule growth inhibitor, for metastatic breast cancer patients.
She describes the benefits to patients, with a complete and objective responses recorded at this interim analysis, which she notes as being independent of PD-L1 positivity in samples.
Dr Tolaney considers the toxicity profile of checkpoint inhibitory therapy, and the broader future of immunotherapy for breast cancer.
ASCO GU 2026: Updates in bladder cancer
Tepotinib in second line NSCLC treatment
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
OncoAlert Round Up for August 25th - 31st, 2023
